Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsVaccine, 2012
- The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infectionJournal of Clinical Investigation, 2012
- A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosisNature Medicine, 2011
- Viruses—from pathogens to vaccine carriersCurrent Opinion in Virology, 2011
- The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in AdultsAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosisJournal of Experimental Medicine, 2010
- Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cellsJournal of Experimental Medicine, 2009
- Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungsJournal of Experimental Medicine, 2007
- Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma InterferonInfection and Immunity, 2007
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus VectorThe Journal of Infectious Diseases, 2006